PDCD1 and neoplasm: These data suggest that the tumor-specific PD-1+ TCF-1+ T cell reservoir in the TdLN are the source of the increase in tumor PD-1+ TCF-1+ and PD-1+ TCF-1- T cells following combination therapy as well as the enhanced tumor control.